Abstract
Oxidative stress represents a fundamental pathological mechanism connecting metabolic dysfunction, chronic inflammation, and progressive cellular injury. Emerging evidence indicates that glucagon-like peptide-1 (GLP-1) receptor signaling extends beyond its classical incretin function in glucose regulation and acts as a critical molecular interface between metabolic control, redox homeostasis, and cellular protection [1–3]. Activation of GLP-1 pathways by endogenous peptide or GLP-1 receptor agonists regulates intracellular signaling networks involved in oxidative stress modulation, inflammatory suppression, and tissue preservation [1,4].
At the molecular level, GLP-1 receptor activation stimulates cAMP-dependent signaling pathways, including protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), which promote adaptive cellular responses and enhance endogenous antioxidant capacity [2,3]. A major downstream mechanism involves activation of the Nrf2–Keap1 antioxidant pathway, a master regulator of cellular redox balance, resulting in increased expression of antioxidant enzymes, including glutathione peroxidase (GPx) and other components of the glutathione (GSH) system [5,6]. These coordinated responses facilitate efficient detoxification of reactive oxygen species (ROS) and protect cellular macromolecules from oxidative injury [5–7].
Excessive reactive oxygen species accumulation contributes to mitochondrial dysfunction, lipid peroxidation, protein oxidation, and oxidative DNA damage, thereby accelerating the progression of type 2 diabetes mellitus, cardiovascular disorders, and other metabolic diseases [4,7]. GLP-1 signaling counteracts these pathological processes by improving metabolic efficiency, reducing inflammatory activation, and suppressing key pro-inflammatory pathways, particularly NF-κB signaling [4,8].
The protective actions of GLP-1 extend across multiple biological systems, including vascular tissues, metabolic organs, and circulating blood components [8,9]. In erythrocytes, which lack mitochondria and nuclei, antioxidant protection depends primarily on enzymatic and non-enzymatic defense systems, particularly the glutathione-dependent antioxidant network [6,10]. Therefore, erythrocyte preservation reflects systemic regulation of oxidative balance rather than direct organelle-mediated antioxidant activity [10].
Overall, GLP-1 receptor signaling represents a clinically relevant regulatory axis integrating metabolic signaling, oxidative stress regulation, inflammatory control, and cellular survival mechanisms [1–4,6]. This molecular framework highlights GLP-1-based therapies as promising interventions for oxidative stress-related diseases, metabolic disorders, and conditions characterized by impaired redox regulation.
Keywords
GLP-1 receptor signaling; oxidative stress; redox homeostasis; antioxidant defense mechanisms; reactive oxygen species (ROS); Nrf2–Keap1 pathway; glutathione system; metabolic inflammation; mitochondrial dysfunction; cellular protection
1. Introduction
Metabolic disorders, including type 2 diabetes mellitus, obesity, and cardiovascular disease, are increasingly recognized as complex conditions characterized by persistent oxidative imbalance and chronic low-grade inflammation. Excessive generation of reactive oxygen species (ROS) combined with impaired antioxidant defense capacity promotes molecular damage, vascular dysfunction, insulin resistance, and progressive cellular deterioration [4,7,11].
Although glucagon-like peptide-1 (GLP-1) was initially identified as an incretin hormone responsible for glucose-dependent insulin secretion, extensive research has expanded its biological significance beyond glucose regulation. Current evidence demonstrates that GLP-1 receptor activation functions as an important regulator of metabolic adaptation, inflammatory modulation, mitochondrial stability, and cell survival pathways [1–3]. Pharmacological GLP-1 receptor agonists exhibit therapeutic effects extending beyond glycemic improvement, including attenuation of oxidative stress, enhancement of endothelial function, and protection against metabolic stress-induced cellular injury [1–3,8,12].
The interaction between metabolism and oxidative regulation represents a complex biological network involving hormonal signals, intracellular transduction pathways, and endogenous antioxidant systems. Disruption of redox homeostasis promotes metabolic inflammation, activates stress-responsive pathways such as NF-κB signaling, and accelerates molecular damage involving lipid peroxidation, protein oxidation, and oxidative DNA modification [4–6,13].
Recent studies indicate that GLP-1-dependent mechanisms restore cellular equilibrium through enhancement of endogenous antioxidant responses and regulation of key transcriptional defense systems. Among these pathways, the Nrf2–Keap1 signaling axis represents a central regulator of cellular antioxidant defense, controlling the expression of cytoprotective enzymes involved in ROS elimination and maintenance of intracellular redox stability. Through regulation of the glutathione (GSH) system and antioxidant enzymes, GLP-1 signaling contributes to preservation of physiological oxidative balance [5,6,14].
Importantly, experimental and clinical evidence demonstrates that GLP-1 receptor agonists exert significant anti-inflammatory and antioxidant effects in vascular and metabolic tissues. These effects include reduction of endothelial oxidative stress, improvement of nitric oxide bioavailability, attenuation of inflammatory mediator production, and protection against chronic metabolic injury [8,9,15].
Understanding the molecular relationship between GLP-1 signaling and oxidative stress regulation provides important insight into emerging therapeutic approaches targeting metabolic disease, inflammatory disorders, and redox-associated cellular damage. This integrated perspective positions GLP-1 as a key molecular regulator connecting metabolism, inflammation, antioxidant defense, and long-term tissue protection [1–6,12,14].
2. Molecular Mechanisms of GLP-1 Receptor Signaling in Redox Regulation
The biological effects of glucagon-like peptide-1 (GLP-1) are initiated through binding to the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor (GPCR) expressed in multiple tissues, including pancreatic β-cells, cardiovascular tissues, immune cells, and metabolic organs [1–3]. Following receptor activation, intracellular signaling is primarily mediated through stimulation of adenylate cyclase, resulting in increased production of cyclic adenosine monophosphate (cAMP) and activation of downstream signaling pathways involved in metabolic adaptation and cellular stress resistance [1–3].
The cAMP-dependent signaling cascade, particularly protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) pathways, represents a central molecular mechanism through which GLP-1 regulates redox homeostasis, mitochondrial function, inflammation, and antioxidant defense. These signaling pathways coordinate multiple intracellular responses that improve cellular adaptation under conditions of metabolic stress and excessive reactive oxygen species (ROS) generation [2,3,8].
A major consequence of GLP-1 receptor activation is modulation of the Nrf2–Keap1 antioxidant pathway, which functions as a primary transcriptional regulator of cellular defense against oxidative injury. Activation of Nrf2 promotes expression of antioxidant and detoxification genes, including enzymes associated with the glutathione (GSH) system, glutathione peroxidase (GPx) activity, and other cytoprotective proteins involved in maintaining intracellular redox balance [5,6,14]. Through enhancement of these antioxidant mechanisms, GLP-1 signaling limits excessive ROS accumulation and reduces oxidative damage to cellular macromolecules [5–7].
In parallel, GLP-1 receptor signaling regulates inflammatory pathways that contribute to metabolic dysfunction. A key mechanism involves suppression of excessive NF-κB activation, a major transcriptional pathway responsible for regulating pro-inflammatory cytokines, adhesion molecules, and mediators involved in chronic metabolic inflammation. By reducing NF-κB-dependent inflammatory responses, GLP-1 contributes to restoration of the balance between inflammatory signaling and antioxidant protection [4,13].
Beyond intracellular antioxidant regulation, GLP-1 signaling improves vascular redox function by enhancing endothelial nitric oxide (NO) availability, reducing endothelial oxidative stress, and improving vascular responsiveness. These mechanisms are particularly important in cardiovascular tissues, where oxidative injury and inflammation contribute to endothelial dysfunction, atherosclerosis, and cardiometabolic complications [8,9,15].
Collectively, GLP-1 receptor signaling functions as an integrated molecular regulator connecting hormonal regulation, oxidative stress control, inflammatory modulation, and cellular survival pathways. Rather than acting through a single antioxidant mechanism, GLP-1 coordinates multiple signaling networks that collectively preserve cellular redox homeostasis and metabolic stability [1–6,12].
3. GLP-1 and Antioxidant Defense Mechanisms
Oxidative stress develops when the production of reactive oxygen species (ROS) exceeds the capacity of endogenous antioxidant systems, resulting in disruption of cellular redox balance and progressive molecular injury. To maintain physiological function, cells rely on coordinated enzymatic and non-enzymatic antioxidant defense mechanisms that neutralize reactive molecules and prevent oxidative propagation reactions [5–8].
Among these protective systems, the glutathione (GSH) antioxidant pathway represents one of the most important intracellular mechanisms for maintaining redox stability. Reduced glutathione (GSH) functions as a major antioxidant reservoir by directly scavenging reactive species and serving as a substrate for glutathione-dependent enzymes, particularly glutathione peroxidase (GPx) [6–8]. Maintenance of adequate GSH availability is essential for protecting proteins, lipids, and nucleic acids against oxidative modification.
The activity of glutathione peroxidase facilitates the conversion of hydrogen peroxide (H₂O₂) into water, thereby preventing the formation of highly reactive secondary oxidants. Together with superoxide dismutase (SOD) and catalase, this enzymatic network forms a coordinated antioxidant defense system responsible for controlling intracellular ROS levels and preserving cellular integrity [6–9].
Evidence indicates that GLP-1 signaling enhances endogenous antioxidant capacity through regulation of intracellular pathways involved in redox adaptation. Activation of GLP-1 receptors promotes antioxidant responses through modulation of transcriptional regulators, particularly the Nrf2 pathway, resulting in increased expression of antioxidant enzymes and improved resistance against oxidative damage [1–6].
These antioxidant effects are highly relevant in tissues exposed to chronic metabolic stress, including pancreatic β-cells, vascular endothelium, liver, and skeletal muscle. In these organs, excessive ROS production contributes to impaired insulin signaling, mitochondrial dysfunction, inflammation, and progressive tissue injury. By strengthening antioxidant defense systems, GLP-1 contributes to improved metabolic resilience, reduced oxidative burden, and preservation of cellular function [1–6].
Therefore, the relationship between GLP-1 and antioxidant defense mechanisms represents an important biological link between metabolic regulation and protection against oxidative injury. Through enhancement of endogenous antioxidant networks, GLP-1-based therapies provide a potential strategy for targeting diseases associated with impaired redox regulation and chronic metabolic inflammation.
4. Oxidative Damage: Lipids, Proteins, and DNA
Oxidative stress represents a major molecular mechanism underlying cellular dysfunction, in which excessive accumulation of reactive oxygen species (ROS) exceeds endogenous antioxidant capacity and promotes progressive damage to essential biological molecules. Disruption of redox homeostasis affects multiple cellular compartments, resulting in oxidative modification of lipids, proteins, and nucleic acids and contributing to the development of chronic metabolic and degenerative disorders [4–7].
4.1 Lipid Peroxidation and Membrane Dysfunction
Cellular membranes are among the primary targets of oxidative injury because of their high content of polyunsaturated fatty acids. ROS-mediated abstraction of hydrogen atoms from membrane lipids initiates a self-propagating lipid peroxidation cascade, resulting in structural and functional disruption of phospholipid bilayers [4–7].
The progression of lipid peroxidation generates reactive aldehydes, particularly malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which function as secondary oxidative mediators capable of modifying proteins, altering signaling pathways, and amplifying cellular injury. Accumulation of these lipid-derived electrophiles affects membrane fluidity, receptor function, ion transport, and mitochondrial membrane stability, thereby linking oxidative damage with metabolic dysfunction and inflammatory activation [4–7].
In metabolic diseases, excessive lipid oxidation contributes to insulin resistance, endothelial dysfunction, and impaired cellular communication. Through improvement of antioxidant defense systems and reduction of ROS production, GLP-1 receptor signaling may attenuate lipid peroxidation and preserve membrane integrity in metabolically vulnerable tissues [1–6].
4.2 Protein Oxidation and Loss of Cellular Function
Proteins represent another major target of oxidative molecular damage. Reactive oxygen species can modify amino acid residues, particularly cysteine, methionine, and tyrosine, leading to protein carbonylation, abnormal disulfide formation, structural instability, and impaired biological activity [4–7].
Oxidative modification of enzymes can reduce catalytic efficiency, disrupt metabolic pathways, and impair cellular signaling networks. Furthermore, accumulation of oxidized or misfolded proteins may exceed proteasomal degradation capacity, promoting proteotoxic stress and cellular dysfunction. These effects are especially significant in tissues with high metabolic activity, where continuous protein turnover and enzymatic regulation are essential for maintaining physiological function [4–7].
By reducing excessive ROS generation and enhancing endogenous antioxidant responses, GLP-1-based therapies may contribute to preservation of protein stability and improved cellular stress adaptation. Activation of antioxidant pathways, including the Nrf2–Keap1 signaling pathway, provides an important mechanism through which GLP-1 limits oxidative protein injury [5,6,14].
4.3 Oxidative DNA Damage and Genomic Stability
Beyond lipid and protein oxidation, oxidative DNA damage represents a critical consequence of prolonged ROS exposure. Reactive oxygen species interact with nucleic acids, producing base modifications, DNA strand breaks, and chromosomal instability [4–7].
One of the most extensively studied biomarkers of oxidative DNA injury is 8-hydroxy-2′-deoxyguanosine (8-OHdG), which reflects oxidative modification of guanine residues and is associated with impaired DNA replication, mutagenesis, and altered cellular function [4–7]. Although DNA repair mechanisms can correct many oxidative lesions, persistent oxidative stress may overwhelm repair capacity, resulting in cellular senescence, apoptosis, or pathological transformation.
The protective effects of GLP-1 receptor activation against oxidative injury are mediated primarily through systemic regulation of metabolism, inflammation, and antioxidant capacity. By improving mitochondrial efficiency, reducing glucotoxicity and lipotoxicity, and enhancing antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx), GLP-1 signaling contributes to preservation of genomic stability and cellular function [1–6].
Collectively, oxidative modification of lipids, proteins, and DNA represents an interconnected network of molecular injury that drives metabolic disease progression. The ability of GLP-1 signaling to regulate oxidative stress, inflammation, and antioxidant defense mechanisms highlights its importance as a therapeutic pathway for maintaining cellular protection and redox balance.
5. GLP-1, Mitochondrial Oxidative Stress, and Metabolic Adaptation
Mitochondrial dysfunction is a central feature of metabolic disorders and a major contributor to cellular injury. Mitochondria represent the primary intracellular source of reactive oxygen species (ROS) under physiological and pathological conditions, mainly generated as by-products of oxidative phosphorylation within the electron transport chain [4–8].
Under normal conditions, mitochondrial antioxidant systems maintain ROS production within physiological limits. However, metabolic overload, excessive nutrient availability, inflammation, and impaired electron transport increase electron leakage and promote excessive ROS generation. This condition, known as mitochondrial oxidative stress, results in reduced ATP production, impaired bioenergetic efficiency, mitochondrial membrane instability, and activation of apoptotic signaling pathways [4–8].
These mitochondrial abnormalities are strongly associated with insulin resistance, cardiovascular disease, obesity-related complications, and progressive organ dysfunction. Therefore, maintaining mitochondrial quality control and metabolic adaptation represents a critical component of cellular protection against oxidative injury [4–8].
GLP-1 receptor signaling has emerged as an important regulator of mitochondrial homeostasis through activation of intracellular pathways involving cAMP, PKA, and EPAC signaling. These pathways enhance mitochondrial efficiency by improving substrate utilization, regulating oxidative phosphorylation, and reducing pathological electron leakage from respiratory complexes [2–5].
A key effect of GLP-1 signaling is promotion of mitochondrial biogenesis, which supports renewal of mitochondrial populations and improves cellular energetic capacity. Enhanced mitochondrial function contributes to improved ATP production, stabilization of mitochondrial membrane potential, and reduction of excessive ROS generation [2–5].
These mechanisms are particularly relevant in metabolically active tissues, including cardiac muscle, liver, skeletal muscle, and pancreatic β-cells. In these organs, GLP-1 signaling improves metabolic flexibility, enhances resistance to cellular stress, and reduces vulnerability to energy imbalance caused by chronic metabolic overload [1–6].
Importantly, GLP-1 does not directly function as a mitochondrial antioxidant or interact directly with mitochondrial DNA. Instead, its protective mitochondrial effects occur mainly through systemic metabolic regulation. By improving glucose metabolism, reducing lipid accumulation, and suppressing inflammatory signaling, GLP-1 decreases mitochondrial substrate overload and indirectly limits oxidative stress at its source [3–7].
Overall, the interaction between GLP-1 signaling, mitochondrial function, and oxidative stress regulation establishes GLP-1 as an upstream metabolic regulator capable of integrating energy metabolism, antioxidant defense, and cellular adaptation.
6. GLP-1 and Inflammatory Signaling Pathways
Chronic inflammation represents a major pathological component of metabolic disorders and is closely interconnected with oxidative stress. Persistent activation of inflammatory pathways promotes excessive production of reactive oxygen species (ROS), disrupts redox homeostasis, and accelerates progressive cellular and tissue injury [4–7].
A central regulator of inflammation-associated oxidative damage is the nuclear factor-kappa B (NF-κB) signaling pathway, a transcriptional system responsible for controlling the expression of numerous pro-inflammatory genes, including cytokines, chemokines, adhesion molecules, and stress-responsive mediators [4,7]. Under conditions of chronic metabolic stress, sustained NF-κB activation contributes to metabolic inflammation, endothelial dysfunction, impaired insulin signaling, and increased oxidative burden, creating a self-amplifying cycle between inflammation and cellular damage [4,7].
GLP-1 receptor signaling exerts important anti-inflammatory effects by regulating inflammatory transcriptional networks and reducing excessive NF-κB activation. Through suppression of NF-κB-dependent gene expression, GLP-1 decreases production of inflammatory mediators and limits chronic inflammatory responses associated with obesity, diabetes, and cardiovascular disease [1–3,8].
In addition to inhibiting inflammatory pathways, GLP-1 enhances activation of the Nrf2 antioxidant pathway, thereby promoting expression of cytoprotective genes involved in ROS detoxification and cellular defense. This coordinated regulation of inflammatory and antioxidant mechanisms establishes GLP-1 as a molecular link between immune modulation, oxidative stress control, and metabolic adaptation [5,6].
The interaction between GLP-1 and inflammatory signaling is particularly important in vascular tissues. Endothelial oxidative stress and inflammation are major contributors to atherosclerosis, vascular dysfunction, and cardiovascular complications associated with metabolic diseases. GLP-1 receptor agonists have demonstrated the ability to improve endothelial function, increase nitric oxide bioavailability, reduce oxidative injury, and suppress inflammatory activation within vascular cells [8,9,15].
Therefore, GLP-1-based therapies represent a broader pharmacological approach that extends beyond glucose regulation by targeting the interconnected pathways of metabolic inflammation, oxidative stress, and cellular protection. Through simultaneous modulation of inflammatory signaling and antioxidant defense, GLP-1 contributes to restoration of physiological balance in metabolically stressed tissues [1–6].
7. Erythrocyte Oxidative Protection and Systemic Redox Balance
Erythrocytes (red blood cells; RBCs) represent a unique biological system continuously exposed to oxidative challenges because of their essential role in oxygen transport and continuous interaction with hemoglobin oxidation–reduction cycles. Despite their vulnerability to oxidative reactions, mature erythrocytes lack both nuclei and mitochondria, making them entirely dependent on cytoplasmic antioxidant mechanisms for maintaining structural integrity and functional survival [4–7].
The primary protective mechanism in erythrocytes is the glutathione (GSH)-dependent antioxidant system, which plays a fundamental role in preserving membrane stability, regulating intracellular redox status, and preventing excessive oxidation of hemoglobin to methemoglobin (metHb). Reduced glutathione acts as a major antioxidant buffer, while enzymes such as glutathione peroxidase (GPx) and glutathione reductase (GR) maintain continuous recycling of oxidized and reduced glutathione pools [6–9].
Glutathione peroxidase contributes to erythrocyte antioxidant protection by catalyzing the reduction of hydrogen peroxide (H₂O₂) into water, thereby preventing accumulation of highly reactive oxidants. In cooperation with additional antioxidant enzymes, including superoxide dismutase and catalase, these systems protect erythrocyte membranes from lipid peroxidation and preserve hemoglobin functionality during prolonged oxidative exposure [6–9].
Although GLP-1 signaling has significant antioxidant and anti-inflammatory effects in metabolic tissues, erythrocytes themselves are unlikely to represent a direct cellular target of GLP-1 receptor activation because mature RBCs lack nuclei, mitochondria, and receptor-mediated transcriptional machinery. Instead, GLP-1 influences erythrocyte oxidative stability indirectly through systemic metabolic regulation [1–6].
Improved glucose control, reduced metabolic inflammation, decreased circulating reactive oxygen species (ROS), and enhanced systemic antioxidant capacity may collectively reduce oxidative pressure on erythrocytes. By lowering exposure to hyperglycemia-induced oxidative stress and inflammatory mediators, GLP-1-based therapies may contribute to preservation of erythrocyte membrane integrity, deformability, oxygen delivery capacity, and cellular lifespan [1–6].
This systemic perspective highlights an important distinction: GLP-1 does not directly modify erythrocyte antioxidant enzymes but rather improves the extracellular metabolic environment that determines erythrocyte oxidative burden. Therefore, erythrocyte protection represents an indirect consequence of improved whole-body redox homeostasis and reduced metabolic stress [2–6].
Overall, the relationship between GLP-1, erythrocyte oxidative defense, and systemic antioxidant regulation demonstrates how metabolic therapies can influence circulating blood components through upstream modulation of inflammation and oxidative balance.
8. Clinical Implications and Therapeutic Perspectives
The expanding understanding of GLP-1 receptor signaling has transformed the perception of GLP-1-based therapies from glucose-lowering interventions into multifunctional treatments targeting interconnected pathways of metabolism, inflammation, oxidative stress, and cellular protection. Although originally developed for glycemic regulation in type 2 diabetes mellitus, GLP-1 receptor agonists demonstrate broader biological effects involving cardiovascular protection, metabolic improvement, and regulation of systemic redox balance [1–3].
A major therapeutic implication of GLP-1 activity is its ability to restore redox homeostasis in conditions characterized by excessive reactive oxygen species (ROS) production. Chronic oxidative stress contributes to lipid peroxidation, protein oxidation, mitochondrial dysfunction, and oxidative DNA damage, which collectively accelerate tissue deterioration in metabolic and degenerative diseases [4–7]. Through enhancement of endogenous antioxidant pathways, including activation of the Nrf2–Keap1 pathway and improvement of the glutathione (GSH) antioxidant system, GLP-1 signaling may reduce oxidative injury and improve cellular resilience [5,6].
The cardiovascular benefits of GLP-1-based therapies are closely associated with their effects on endothelial function and vascular oxidative regulation. By reducing endothelial ROS generation, improving nitric oxide bioavailability, and suppressing inflammatory activation, GLP-1 receptor agonists contribute to improved vascular homeostasis and reduced cardiovascular risk in metabolically compromised patients [8,9,15]. These mechanisms support the concept that GLP-1 functions as a regulator of cardiometabolic protection rather than merely a mediator of glucose control.
Beyond metabolic and cardiovascular disorders, modulation of oxidative and inflammatory pathways suggests potential therapeutic relevance in diseases where chronic redox imbalance contributes to progression. Conditions including neurodegenerative disorders, chronic kidney disease, and inflammatory diseases involve converging mechanisms of oxidative injury, mitochondrial dysfunction, and immune activation [4,7,10]. Therefore, targeting GLP-1 signaling may provide a broader strategy for controlling disease-associated oxidative damage.
The integration of metabolic signaling pathways with redox biology represents an emerging framework in modern therapeutics. Unlike conventional antioxidant approaches that directly neutralize free radicals, GLP-1-based interventions regulate upstream biological mechanisms controlling ROS generation, inflammation, mitochondrial efficiency, and endogenous antioxidant capacity [1–6]. This multi-target regulatory effect highlights the potential of GLP-1 receptor agonists as therapeutic agents for diseases characterized by impaired metabolic adaptation and oxidative imbalance.
Future investigations should further clarify tissue-specific GLP-1 mechanisms, identify biomarkers of antioxidant response, and determine whether long-term modulation of GLP-1 signaling provides clinical benefits in oxidative stress-associated disorders beyond established metabolic indications.
9. Conclusion
Glucagon-like peptide-1 (GLP-1) has emerged as a multifunctional metabolic regulator that extends substantially beyond its classical role in glucose-dependent insulin secretion. Increasing evidence demonstrates that GLP-1 receptor signaling (GLP-1R) represents a central molecular pathway connecting metabolic regulation, oxidative stress control, inflammatory modulation, and cellular survival mechanisms.
Through activation of intracellular signaling networks, including cAMP–PKA and EPAC pathways, GLP-1 enhances endogenous antioxidant capacity by regulating key defense systems such as superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), and the glutathione (GSH) system. These responses strengthen cellular resistance against excessive reactive oxygen species (ROS) accumulation and contribute to preservation of redox homeostasis.
GLP-1-mediated regulation of oxidative pathways also reduces molecular damage involving lipid peroxidation, protein oxidation, and oxidative DNA injury. In parallel, suppression of NF-κB-dependent inflammatory signaling and activation of the Nrf2 antioxidant pathway establish GLP-1 as an important molecular interface between inflammation and oxidative defense.
Although GLP-1 does not directly function as a mitochondrial antioxidant or act directly on erythrocytes, its systemic effects indirectly improve the stability of these systems by reducing glucotoxicity, lipotoxicity, mitochondrial stress, and chronic inflammatory burden. This systemic mechanism explains how GLP-1-based therapies can influence multiple organs and biological compartments through coordinated regulation of metabolism and oxidative balance.
Overall, GLP-1 receptor agonists represent promising therapeutic strategies for diseases characterized by impaired redox regulation, including metabolic disorders, cardiovascular disease, neurodegenerative conditions, and chronic inflammatory states. The integration of GLP-1 biology with oxidative stress research provides a foundation for future translational approaches aimed at restoring metabolic flexibility, reducing cellular injury, and promoting long-term tissue protection.
References
1.Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.
2.Campbell JE, Drucker DJ. Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metab. 2013;17(6):819-837.
3.Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiol Rev. 2007;87(4):1409-1439.
4.Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058-1070.
5.Uruno A, Motohashi H. The Keap1–Nrf2 system as an in vivo sensor for electrophiles. Nitric Oxide. 2011;25(2):153-160.
7.Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183.
8. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187–215. 13;12:130.
11.Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84(21-22):705-712.
12.Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311-322.
13.Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011;21(1):103-115.
